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BACKGROUND & AIMS: Esophageal squamous cell carcinoma
(ESCC) is the predominant form of esophageal cancer in Japan.
Smoking and drinking alcohol are environmental risk factors for
ESCC, whereas single nucleotide polymorphisms in ADH1B and
ALDH2, which increase harmful intermediates produced by
drinking alcohol, are genetic risk factors. We conducted a large-
scale genomic analysis of ESCCs from patients in Japan to deter-
mine the mutational landscape of this cancer. METHODS: We
performed whole-exome sequence analysis of tumor and non-
tumor esophageal tissues collected from 144 patients with ESCC
who underwent surgery at 5 hospitals in Japan. We also per-
formed single-nucleotide polymorphism array-based copy num-
ber proﬁle and germline genotype analyses of polymorphisms in
ADH1B and ALDH2. Polymorphisms in CYP2A6, which increase
harmful effects of smoking, were analyzed. Functions of TET2
mutants were evaluated in KYSE410 and HEK293FT cells.
RESULTS: A high proportion of mutations in the 144 tumor
samples were C to T substitution in CpG dinucleotides (called the
CpG signature) and C to G/T substitutions with a ﬂanking 50
thymine (called the APOBEC signature). Based on mutationalsignatures, patients were assigned to 3 groups, which associated
with environmental (drinking and smoking) and genetic (poly-
morphisms in ALDH2 and CYP2A6) factors. Many tumors con-
tained mutations in genes that regulate the cell cycle (TP53,
CCND1, CDKN2A, FBXW7); epigenetic processes (MLL2, EP300,
CREBBP, TET2); and the NOTCH (NOTCH1, NOTCH3), WNT (FAT1,
YAP1, AJUBA) and receptor-tyrosine kinasephosphoinositide 3-
kinase signaling pathways (PIK3CA, EGFR, ERBB2). Mutations in
EP300 and TET2 correlated with shorter survival times, and
mutations in ZNF750 associated with an increased number
of mutations of the APOBEC signature. Expression of mutant
forms of TET2 did not increase cellular levels of 5-
hydroxymethylcytosine in HEK293FT cells, whereas knockdown
of TET2 increased the invasive activity of KYSE410 ESCC cells.
Computational analyses associated the mutations in NFE2L2 we
identiﬁed with transcriptional activation of its target genes.
CONCLUSIONS:We associated environmental and genetic factors
with base substitution patterns of somatic mutations and provide
a registry of genes and pathways that are disrupted in ESCCs.
These ﬁndings might be used to design speciﬁc treatments for
patients with esophageal squamous cancers.
Keywords: Mutational Signature; Exome Sequencing; Copy
Number Proﬁling; Esophagus.
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whole-exome sequencing.
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Open access under CC BY-NC-ND license.showing lymph node metastasis and tumor invasion into
adjacent organs, even in the early stages.1,2 In contrast to
the predominance of adenocarcinoma in Western countries,
squamous cell histology represents the most prevalent form
of esophageal cancer in East Asia, including Japan and China.
In Japan, ESCC is the tenth most common malignancy
and the seventh most common cause of cancer-related
deaths. Epidemiologic studies have established that drink-
ing and smoking are strong risk factors for developing
ESCC.3 Furthermore, genetic polymorphisms that impair the
functions of alcohol-metabolizing enzymes have been re-
ported as risk factors. Our previous genome-wide associa-
tion studies have shown that functional single-nucleotide
polymorphisms (SNPs) in 2 alcohol dehydrogenase genes,
ADH1B (rs1229984 GG) and ALDH2 (rs671 AG/AA), in-
crease the incidence of ESCC in Japanese cohorts.4 These
ﬁndings are consistent with data from another independent
study.5 Notably, there is drastic synergy among these ge-
netic and environmental risk factors; our study showed that
the incidence odds ratio was as high as 146.4 (95% conﬁ-
dence interval [CI]: 50.5424.5) in the presence of all 4 risk
factors.
In China, the incidence and mortality rates of ESCC are
higher than those in Japan. ESCC is the fourth most
frequently diagnosed cancer and the fourth leading cause of
cancer-related deaths in China. There are substantial dif-
ferences in the epidemiology3 of ESCC between the Japanese
and Chinese populations. The association of smoking and
drinking with the risk of developing ESCC appears to be
weaker in China than in Japan. Notably, a regional bias exists
in the incidence of Chinese ESCC. Although the incidence
rate is generally higher in rural areas than in urban areas
throughout China, some rural areas have reported particu-
larly high incidences. In the high-incidence areas, the asso-
ciation between the incidence rate and drinking and
smoking behavior is especially weak; instead, family history
and environmental factors, such as nutritional deﬁciency
and food mutagens, are proposed risk factors.6–8
Recently, several whole-exome sequencing (WES)
studies have revealed different landscapes of driver genes,
as well as somatically disrupted pathways in ESCC.9,10
Notably, 3 large-scale WES studies of ESCC cohorts have
been carried out in China; Gao et al11 evaluated a low-
incidence cohort from an urban area near Beijing, while
Song et al12 and Zhang et al13 examined high-incidence co-
horts from the Chaoshan District of Guangdong Province
and the Taihang Mountains of north central China, respec-
tively. However, no comprehensive genomic proﬁling of a
Japanese ESCC cohort has been reported.
Here, we present the landscape of genomic alterations in
Japanese ESCC patients obtained by WES and/or SNP array-
based copy number (CN) analysis in 144 Japanese patients.
This study not only expands the registry of somatically
disrupted driver genes, but also reveals the association of
genotypeenvironment interactions with mutational sig-
natures that are unique to the Japanese ESCC cohort.Material and Methods
Sample Collection
Samples from 144 patients with diagnosed ESCC were ob-
tained from 5 hospitals (Juntendo University Hospital, National
Cancer Center Hospital, Kurume University Hospital, Saitama
Cancer Center, and Kagoshima University Hospital). Written
informed consent was obtained from all patients and the study
protocol was reviewed and approved by the internal review
board of Kyushu University.Whole-Exome Sequencing
DNA extracted from ESCC and paired normal samples was
captured using the SureSelect Human All Exon 50Mb Kit (Agi-
lent Technologies, Santa Clara, CA) following the manufac-
turer’s instructions. Captured DNA was sequenced using the
HiSeq2000 and paired-end (75100 bp) sequencing reads
were generated for each sample. Mutation calling was per-
formed using the EBcall algorithm14 (http://genomon.hgc.jp/
exome/en/index.html).Copy Number Proﬁling
DNA was processed and hybridized to the Human-
OmniExpress BeadChip (HumanOmniExpress BeadChip Kit;
Illumina, San Diego, CA) following the manufacturer’s protocol.
GenomeStudio (Illumina) was used to obtain B-allele frequencies
and normalized logarithmic probe intensities, which were used
as input data for an ASCAT analysis to estimate CN proﬁles along
with tumor ploidy and aberrant cell fraction.15 For details,
please see the Supplementary Material and Methods.Results
Effects of Environmental/Genetic Factors on
Mutational Signatures
Tumor and paired normal DNA from 144 Japanese ESCC
patients were subjected to WES. The mean read depth was
120 and 91.1% of target bases were covered by >10 inde-
pendent reads (SupplementaryTables1and2).A total of23,121
somatic events, including22,175single-nucleotide substitutions
and 946 short insertions and deletions (indels), were identiﬁed.
The mean number of mutations was 161 (range, 47644) per
sample or 3.10 (range, 0.9112.4) per megabase across the
target exome sequences (Figure 2A and Supplementary
Table 3). Similar to previous ﬁndings for many cancer types,
thepredominant substitutionacross all ESCCsampleswasC toT
involving the CpG dinucleotide (Figure 1A).16 In addition, C to
May 2016 Genomic Landscape of Japanese ESCC 1173G/T substitutions with a ﬂanking 50 thymine characterized the
ESCC genomes, particularlywhen the 30 basewas T or A. Recent
studies have reported that APOBEC-mediated mutagenesis is
associatedwith this signature.17Overall signatureproﬁlesbased
on their trinucleotide context (mutation spectra) were quite
similar to those of Chinese ESCC cohorts from high- and low-
incidence areas,11–13 head and neck squamous cell carcinoma
(HNSCC),18 and, to a lesser degree, lung squamous cell carci-
noma (Supplementary Figure 1).19 However, these signaturesFigure 1. Analysis of mu-
tation spectra. (A) ESCC
mutation spectra calcu-
lated from 144 Japanese
ESCC samples subjected
to WES. Base sub-
stitutions were divided into
96 patterns based on mu-
tation type and nucleo-
tides ﬂanking the mutated
base. The height of the bar
represents the proportion
of each substitution
pattern. (B) Stability of the
three mutation spectra
clusters deduced from
negative matrix factoriza-
tion. (C) Association of the
3 clusters with various
factors. To examine the
uneven distribution of
each factor across the 3
clusters, P values were
computed by c2 tests and
signiﬁcance is indicated by
asterisks. (D) ESCC muta-
tion spectra for each of the
3 clusters. (E) Mean muta-
tion counts for each of the
3 clusters. Stacked bars of
different colors represent
mean counts of different
mutation types in each
cluster. The C>G/T sub-
stitutions at TpCpN tri-
nucleotides are referred to
as the APOBEC signature,
while the C>T sub-
stitutions at NpCpG tri-
nucleotides are referred to
as the CpG signature.are distinct from those reported for esophageal adenocarci-
noma.20 suggesting that different carcinogenic mechanisms
underlie the 2 histologic cancer types in the same viscera.
To investigate the origin of mutations in individual ESCC
cases, we performed a mutation-spectra analysis of the 144
ESCC samples (Supplementary Material and Methods). The
samples clustered into 3 distinct groups based on mutation
spectra (Figure 1B and C). Cluster 1 and cluster 3 showed a
high proportion of APOBEC and CpG signatures, respectively,BA
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Figure 2. Identiﬁcation of
driver genes. (A) Land-
scape of genetic alter-
ations across the 144
ESCC samples. The sam-
ples were sorted by muta-
tion rates (top bars), while
genes were sorted by the
proportion of altered sam-
ples (left bars) and their
functional categories. (B,
C) Statistical evaluation of
mutated genes for the 144
Japanese ESCC samples
(B) and 449 pan-ESCC
samples combined with
Chinese high- and low-
incidence ESCC samples
(C). Each gene is repre-
sented as a dot, while their
horizontal and vertical co-
ordinates indicate negative
log10-scaled P values
from 2 statistical tests
evaluating mutation recur-
rence and enrichment of
mutations that potentially
damage protein functions,
respectively. Sizes of dots
represent the proportion of
mutated samples, while
colors of dots represent
negative log10-scaled P
values from a statistical
test to evaluate the pres-
ence of a mutational hot
spot.
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(Figure 1D). Cluster 1 showed a relatively high mutation rate,
which appeared to be explained by an increase in the APOBEC
signature (Figure1E). Similar clusteringbasedon themutation
spectra was observed for high- and low-incidence ESCC in the
Chinese and HNSCC samples (Supplementary Figures 4–8).
These clusters were tightly associated with well-known envi-
ronmental risk factors, including drinking and smoking, as
well as genetic factors (Figure 1C, Supplementary Figure 2A,
and Supplementary Table 5). Heavy drinkers with drinking-
associated ALDH2 risk alleles (rs671 AG/AA) were signiﬁ-
cantly enriched in cluster 1 and cluster 2 (odds ratio ¼ 4.06;
95% CI: 1.918.89; P ¼ .000078, Fisher’s exact test)
compared with cluster 3. The ALDH2 SNP alone was also
signiﬁcantly enriched in cluster 1 and cluster 2 (P ¼ .00086).No signiﬁcant association was observed between the devel-
opment of drinking-associated ESCC and the presence of an
ADH1B risk allele (rs1229984 GG).
Although we previously found a signiﬁcant synergistic
effect of drinking and smoking on ESCC risk,4 smoking alone
was not signiﬁcantly associated with one or more clusters of
the mutation spectra. It has been reported that cytochrome
P450 2A6 (CYP2A6) is involved in the metabolic activation of
tobacco carcinogens, and its null allele is associated with a
lower risk for lung cancer development.21 Therefore, we
statistically analyzed known polymorphisms of CYP2A6 and
found that smokers with a functional CYP2A6 allele
(CYP2A6*1)were signiﬁcantly enriched in cluster 1 compared
with other clusters (OR¼ 2.47; 95%CI: 1.085.73; P¼ .021).
The enrichment was even more signiﬁcant when smokers
May 2016 Genomic Landscape of Japanese ESCC 1175with a functional CYP2A6 allele had additional risk factors,
including drinking behavior and theALDH2 risk alleles (rs671
AG/AA) (OR ¼ 3.69; 95% CI: 1.529.06; P ¼ .0019).
We also examined the correlation between drinking-
related environmental/genetic factors and 3 mutation
spectra clusters in the Chinese ESCC datasets, although we
could not examine smoking-related factors, owing to the
unavailability of CYP2A6 genotype information
(Supplementary Figures 4 and 5). Compared with Japanese
ESCC, the proportion of drinking-related risk factors was
generally low in Chinese ESCC, particularly in the high-
incidence cohort, which is consistent with previous re-
ports (Supplementary Figure 9).3 In Chinese low-incidence
ESCC, we also found that the combined risk of drinking
and the ALDH2 SNP (rs671 AG/AA) was unevenly distrib-
uted across the 3 mutation spectra clusters. However,
enrichment of the combined risk was observed in cluster 2
only, different from the case of Japanese ESCC. Additionally,
in Chinese high-incidence ESCC, all of the few samples
showing the combined risk were contained in cluster 2. This
observation suggests that a small fraction of Chinese high-
incidence ESCC is caused by the same alcohol-related
mechanism as that of Chinese low-incidence ESCC.BA
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Squamous Cell Carcinoma
The 23,121 somatic mutations identiﬁed by WES of the
144 ESCC samples contained 17,189 nonsynonymous muta-
tions in 10,552 genes (Supplementary Tables 3 and 6).
Among these, we identiﬁed 15 signiﬁcantly mutated genes
after evaluating the recurrence and clustering of mutations,
background mutation rates, and predicted effects of indi-
vidual mutations on protein functions (Supplementary
Material and Methods, Figure 2A and B and Supplementary
Table 7). The most frequently mutated gene was TP53
(mutated in 93.1% of our cohort), followed by NOTCH1
(18.6%), MLL2 (18.6%), NFE2L2 (16.7%), ZNF750 (16.7%),
FAT1 (14.6%), PIK3CA (10.4%), EP300 (8.3%), CDKN2A
(8.3%), CREBBP (7.6%), NOTCH3 (7.6%), TET2 (6.3%),
FBXW7 (5.6%), TGFBR2 (5.6%), and AJUBA (4.2%). TP53,
NFE2L2, EP300, CREBBP, and NOTCH1 clearly contained
mutational hot spots (Supplementary Figure 10). Except for
NFE2L2 and PIK3CA, most of these genes exhibited nonsense
and frameshift mutations, suggesting their tumor suppressor
roles. Examination of the Chinese datasets showed that most
of the 15 genes harbored recurrent mutations, but at lower
frequencies (Supplementary Figure 11A, B, and D). In
contrast, a pan-ESCC analysis combining the Japanese and
Chinese datasets revealed 2 additional genes that were
mutated less frequently in our data: RB1 (4.2%) and PTCH1
(3.5%; Figure 2C). Our comparative analysis also conﬁrmed
that most of the signiﬁcantly mutated genes in ESCC were
also mutated in HNSCC, suggesting that the molecular path-
ogenesis is shared between the 2 squamous cell carcinomas
(Supplementary Figure 11C and D).
SNP array-based CN proﬁling to investigate recurrent CN
variations was also performed for 123 of the 144 ESCC
samples (Supplementary Material and Methods andSupplementary Figure 12). Recurrent CN variations
included ampliﬁcations of 3q (69.3%), 8q (64.3%), 5p
(53.7%), 7p (47.2%), and 20q (42.3%); deletions of 3p
(71.5%), 9p (56.1%), 4p (48.9%), 5q (48.0%), and 13p
(47.2%); and loss of heterozygosity in 9p (97.6%), 3p
(92.7%), 9q (83.7%), 13q (76.4%), 13p (73.2%), and 17p
(68.3%) (Figure 3A).22 A number of candidate driver genes
were identiﬁed from recurrent focal CN alterations
(Figure 3B and Supplementary Figure 13). The genes most
frequently affected were CDKN2A/2B (deleted in 47.9%)
and CCND1 (ampliﬁed in 46.5%), followed by TERT
(ampliﬁed in 22.9%), LRP1B (deleted in 20.8%), PCDH
cluster (ampliﬁed in 13.2%), KLF5 (ampliﬁed in 9.0%),
FOXA1 (ampliﬁed in 7.6%), FAM190A (deleted in 7.6%),
EGFR (ampliﬁed in 6.6%), YAP1 (ampliﬁed in 5.6%), HOXA
cluster (ampliﬁed in 4.2%), and ERBB2 (ampliﬁed in 2.3%)
(Figure 3C and Supplementary Figure 14). Notably, CDKN2A,
EGFR, and ERBB2 also harbored recurrent mutations.
By combining CN proﬁling and WES data, we found that
TP53, NOTCH1, ZNF750, FAT1, TET2, FBXW7, and CDKN2A
were frequently subjected to biallelic inactivation via double
mutations, mutations accompanied by loss of heterozygosity
or homozygous deletion (Figure 3D), suggesting that these
genes have tumor suppressive roles. In an evaluation of the
clinical impacts of these mutations/CN variations, we found
that alterations in 4 of these genes were correlated with poor
overall survival: EP300 (P ¼ .000573), TET2 (P ¼ .0177),
LRP1B (P ¼ .00523), and KLF5 (P ¼ .0373; Figure 4A).
Notably, the EP300 data were similar to that of low-incidence
ESCC in the Chinese population.11 We also examined the
correlations between gene mutations and mutational signa-
tures (Figure 4B). Consistent with the results of a previous
study examining high-incidence ESCC in Chinese subjects,13
we found that samples with a higher APOBEC signature ten-
ded to contain 2 types of hot-spot PIK3CA mutations
(P¼ .0012, Figure 4B); these mutations presumably resulted
from a common mutational mechanism, as they are APOBEC
signaturemutations. Similarly, hot-spot frameshift mutations
in TGFBR2 tended to occur in samples with high short indel
rates (P ¼ .0032), as previously observed in a gastric cancer
study.23 Notably, ZNF750 mutations were positively associ-
atedwith theAPOBEC signature (P¼ .00030), consistentwith
the Chinese ESCC and HNSCC datasets (Figure 4B,
Supplementary Figure 15A). ZNF750, an epidermal differen-
tiation regulator,24 has been proposed to be a tumor sup-
pressor gene of ESCC.10,13 This hypothesis was also
supportedby our data,which showed thatmost of the ZNF750
mutations were null mutations accompanied by loss of het-
erozygosity (Figures 2A and 3D). This ﬁnding suggests that
loss of function of ZNF750 contributes to an unknown
mutational mechanism generating the APOBEC signature.Genetically Disrupted Pathways in Esophageal
Squamous Cell Carcinoma
To obtain a more comprehensive understanding of the
molecular lesions in Japanese ESCC, we searched for path-
ways genetically deregulated in our cohort by a literature
review (Figure 5). Cell cycle regulators constituted the most
Figure 3. Analysis of CN
alterations. (A, B) Signiﬁ-
cance of CN alteration re-
currences across
chromosomes. CN gain,
loss, and loss of hetero-
zygosity (LOH) (A) focal
CN gains and losses (B)
were called from SNP
array data of 123 ESCC
paired samples. The
recurrence of each alter-
ation type was then tested
by a Poison-binomial
test,22 and the Benjamini-
Hochberg q values were
obtained to correct for
multiple hypothesis testing
across chromosomal po-
sitions. (C) Focal CN gain
or loss at the CDKN2A,
CCND1, LRP1B, and
HOXA clusters, as well as
the KLF5 and YAP1 loci.
(D) Proportion of samples
showing LOH mutations,
double mutations, and
homozygous deletions in
signiﬁcantly mutated
genes.
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including mutations in TP53 (93.1%), focal ampliﬁcation
of CCND1 (46.5%), and mutation and focal deletion of
CDKN2A (53.5%). Overall, epigenetic regulators comprised
one of the largest gene categories in ESCC as well as other
types of cancers (disrupted in 59.0% of our cohort).26 Two
histone acetyltransferase genes, CREBBP and EP300, were
among the list of signiﬁcantly mutated genes, in which
mutations generally clustered within the HAT domains
(Supplementary Figure 10). Multiple trithorax family genes
were recurrently disrupted,27 whereas few mutationsoccurred in polycomb group complexes, suggesting an
important role of repressive epigenetic marks in the path-
ogenesis of ESCC.
TET2 is involved in epigenetic regulation and is a newly
identiﬁed mutational target in ESCC. It was mutated in 6.3%
of the Japanese cohort. The TET family of proteins encodes
a-ketoglutaratedependent oxygenases that convert 5-
methylcytosine to 5-hydroxymethylcytosine, which is the
initial step of DNA demethylation.28 TET2 has been estab-
lished as a tumor suppressor with prevalent mutations in
hematologic malignancies, and TET2 mutations have
Figure 4. Association of genetic alterations with patient prognosis and mutational signatures. (A) Effect of genetic alterations
on overall survival for 4 signiﬁcant genes. P values were calculated by the log-rank test and the Benjamini-Hochberg q values
were calculated to correct for multiple hypothesis testing performed for multiple genes listed in Figure 2A. (B) Association of
mutations in 3 genes with the APOBEC signature and short indels. The 144 samples were sorted by percentages of each types
of mutation. P values were calculated for the uneven distribution of mutated samples in the sorted list using the Wilcoxon rank
sum test.
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cell renal carcinomas and colorectal cancers.29,30 The simi-
larity in the distribution of TET2 mutations in ESCC with
other types of cancers (Figure 6A) suggests that these may
be loss-of-function mutations. In fact, when transduced into
HEK293FT cells, TET2 mutants identiﬁed in our WES failed
to increase cellular 5-hydroxymethylcytosine levels
compared to wild-type TET2 (Figure 6B). In our ESCC
cohort, TET2 mutations were associated with poor survival
(P ¼ .0177; Figure 4A). In accordance with this, in our
in vitro invasion assay, TET2 knockdown increased the
invasive activity of an ESCC cell line (KYSE410)
(Figure 6CF). In addition, transduction of the wild-type
TET2 allele suppressed the increased invasive activity
compared with the mutant alleles, suggesting a role for the
TET2 mutation in the invasive phenotype of ESCC.
The NRF2 pathway consisting of NFE2L2, KEAP1, and
CUL3 was genetically deregulated in 23.6% of our cohort
(Figure 7A). NFE2L2 (also known as NRF2) encodes a
transcription factor that induces the cellular response to
oxidative stress, whereas KEAP1/CUL-mediated ubiquitina-
tion degrades the NFE2L2 protein under normal condi-
tions.31 Oxidative stress plays important roles in the
development of many cancers, including ESCC, and muta-
tions in the NRF2 pathway have been observed in a wide
variety of squamous cell carcinomas, including ESCC, lung
squamous cell carcinoma, and skin squamous cell carci-
noma.32 These mutations were suggested to contribute to
tumor development by stabilizing the NFE2L2 protein.33
Nearly all NFE2L2 mutations reportedly involve 2 hotspots within or near the DLG and ETGE motifs that bind to
KEAP1, which was also observed in our cohort (Figure 7B).
To assess the functional consequence of NFE2L2 mutations,
we predicted the set of genes transcriptionally regulated by
NFE2L2 in ESCC using transcriptome data from a set of 70
ESCC samples (Supplementary Material and Methods and
Supplementary Figure 16). We then used a set of NFE2L2-
regulated genes previously determined in an in vitro
experiment34 to extract a coherent subset of genes that
were signiﬁcantly co-expressed in the 70 ESCC samples
(Figure 7C).35 As expected, the extracted gene subset, or the
“NFE2L2 module,” was signiﬁcantly enriched for oxidore-
ductase activity-associated genes (P < 1012), such as cy-
tochrome P450, NAD(P)H dehydrogenases, and DP-glucose
6-dehydrogenases (Supplementary Table 9). Accordingly,
we found that the mean expression level of the NFE2L2
module genes, or “NFE2L2 module activity,” was signiﬁ-
cantly higher in NFE2L2-mutated samples than in wild-type
samples (P ¼ 1.29  107; Figure 7C and D). In addition, a
multiple linear regression analysis showed that the NFE2L2
expression level was signiﬁcantly correlated with NFE2L2
module activity in ESCC, regardless of mutation status.
Notably, a similar correlation between the mutation/
expression status of NFE2L2 and NFE2L2 module activity
was conﬁrmed in lung squamous cell carcinoma
(Supplementary Figure 17).
The NOTCH pathway is also a frequent mutational target
in ESCC as well as several other cancer types.36 Combined,
NOTCH1/3 receptors, their ligands (DLL1, DLK1, and JAG2),
and downstream regulators (MAML3, NCOR1/2, and SPEN)
Figure 5. Pathway-level view of genetic alterations. Positive regulation and negative regulation based on a literature review are
indicated as lines with arrowheads and blunt ends, respectively. For each gene, the percentages of altered samples are
provided as numerals in colored boxes (mutations: orange, focal CN gains: focal CN losses: blue). Color strength corresponds
to the percentage. Green bars with numerals indicate the percentage of altered genes in each pathway.
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tations in ESCC were clearly clustered within epidermal
growth factorlike repeats 1112, which are involved in
ligand binding. This mutational hot-spot region is distinct
from the HD-L and PEST domains harboring well-known
oncogenic mutations in T-lymphoblastic leukemia, but
similar to the region harboring presumably tumor-
suppressive mutations in other types of squamous carci-
nomas18,20 (Supplementary Figure 10). The other frequently
disrupted pathways include the receptor-tyrosine
kinasephosphoinositide 3-kinase (RTK/PI3K) and WNT
pathways (disrupted in 31.9% and 26.3% of our cohort,
respectively). Several receptor tyrosine kinases (EGFR,
ERBB2, and ERBB4) and their downstream signal trans-
ducers (PIK3CA, TSC1/2, RICTOR, and MTOR) are mutational
targets in the RTK/PI3K pathway.37,38 Although CTNNB1was not itself affected in the WNT pathway, we found
recurrent mutations in FAT1 and AJUBA, which regulate
CTNNB1 stability39,40; YAP1, which acts cooperatively with
CTNNB141; APC; and AXIN1. By comparing these results with
published data,11–13 we conﬁrmed that mutational land-
scapes at the pathway level were generally conserved across
the different ESCC cohorts (Supplementary Figure 11E).Discussion
In this study, we determined the landscape of genetic
lesions in 144 Japanese ESCC cases by WES and SNP array
proﬁling. Importantly, we identiﬁed 3 mutation spectra
clusters characterized by different proportions of CpG and
APOBEC signatures. Furthermore, these clusters were
associated not only with drinking and smoking, but also
Figure 6. Analysis of TET2 mutations. (A) Mutational types and positions on the TET2 proteins. Pins on the horizontal bar
indicating the TET2 protein denote mutations identiﬁed by our WES. Colored histograms in the background show distributions
of mutational positions in the COSMIC pan-cancer dataset. (B) Evaluation of the expression levels of FLAG-tagged wild-type
or mutant TET2 in KYSE410 cells and dot blot analysis of 5-hydroxymethylcytosine (5hmC) in KYSE410 cells in which FLAG-
tagged wild-type or mutant TET2 was overexpressed. (C) Immunoblot of TET2 in KYSE410 cells in which TET2 was knocked
down by small interfering RNA (siRNA) targeting TET2. (D) Immunoblot of FLAG-tagged TET2 in KYSE410 cells in which TET2
was knocked down by siRNA targeting TET2 and/or the indicated FLAG-tagged TET2 variant was overexpressed. a-Tubulin
was used as a control. (E) Invasion analysis of KYSE410 cells. Viability of the cells that traversed the Matrigel to the lower
surface was measured using CellTiter-Glo. Note that ectopic overexpression of wild-type, but not that of a catalytically inactive
mutant, TET2 suppressed the invasion of KYSE410 cells in which TET2 was knocked down. (F) H&E staining of the invasive
cells in panel (E).
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affect alcohol and tobacco metabolism. We also conﬁrmed
that Chinese high- and low-incidence ESCC cohorts showed
similar mutation spectra clusters, which are associated with
drinking and the ALDH2 SNP; however, the associationpattern differed from that observed in our cohort. Sub-
stantial differences in epidemiologic characteristics have
been reported between Japanese and Chinese ESCC3 and our
unique observations in Japanese ESCC may reﬂect a strong
association between drinking and smoking behaviors and
Figure 7. Analysis of NFE2L2 mutations. (A) Genomic alterations in the NRF2 pathway. (B) Mutational types and positions on
the NFE2L2 protein are the same as in Figure 6A. (C) The NFE2L2 module in ESCC. For NFE2L2 target genes prepared from
in vitro experiments, expression proﬁles in 70 ESCC samples are shown as a clustered heat map. A coherent subset identiﬁed
by extraction of expression modules (EEM)35 and their mean expression proﬁle were obtained as the NFE2L2 module and
module activity, respectively. Note that color bars on the top of the heat map show the NFE2L2 mutation status. The mutations
status and messenger RNA expression level were additively correlated with module activity; the multiple regression coefﬁcients
were 0.89 (P < .001) and 0.53 (P < .001) for mutation and expression, respectively. (D) A box plot of the module activity for
samples with or without a mutation.
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ATESCC incidence in Japan.4,5 In addition, our analysis revealed
that APOBEC signatures are correlated with mutations in a
potential tumor suppressor, ZNF750. Our data suggest that
ESCC cancer genomes are shaped by complex mutational
mechanisms that vary among individual patients, although
the details of these mechanisms remain unclear.
By analyzing a large number of ESCC samples, we also
unveiled the registry of driver genes somatically disrupted
in Japanese ESCC. These genes are dispersed across a
number of known cancer-associated pathways, including
cell cycle and epigenetic regulators, and the NOTCH, NRF2,
WNT, and RTK/PI3K pathways. Biallelic inactivation of TP53
was observed in most of the samples, suggesting an essen-
tial role in tumor initiation. NOTCH1 is frequently disrupted
by loss-of-function hot-spot mutations, supporting that the
loss of NOTCH pathway activity is critical for the growth of
tumor cells with squamous differentiation characteristics.36
TET2 also showed recurrent loss-of-function mutations
associated with poor patient prognosis. Our results
demonstrated that the loss-of-function of TET2 contributes
to the malignant phenotypes of ESCC by enhancing cell
invasiveness, although the detailed mechanisms requirefurther analysis. Notably, TET1, a gene belonging to the
same family, reportedly suppresses cancer invasion by
activating metalloproteinase inhibitors.42 Our informatics
analysis showed that gain-of-function NFE2L2 mutations
transcriptionally activate oxidoreductase-related genes to
oppose oxidative stress, which may play an important role
not only in tumor development, but also in the acquisition of
chemoradiotherapy resistance.43 Our CN analysis revealed a
number of novel driver genes, including LRP1B, KLF5, and
YAP1, which frequently underwent focal CN alterations.
Notably, EGFR, ERBB2, PIK3CA, and other RTK/PI3K
pathway components exhibited recurrent focal ampliﬁca-
tions and/or mutations, indicating that they are potential
targets of molecular-based therapies.37,38 Our data also
suggested that although transducers of canonical WNT
signaling, such as APC and CTNNB1, were not major muta-
tional targets, focal ampliﬁcations of YAP1 and loss-of-
function mutations in FAT1 and AJUBA may contribute to
the activation of WNT signaling in ESCC. A comparison with
published Chinese ESCC datasets suggested that driver
genes and pathways were overall conserved across cohorts.
In summary, this study characterized the genomic landscape
May 2016 Genomic Landscape of Japanese ESCC 1181of Japanese ESCC, which increases the understanding of the
molecular pathophysiology of ESCC and may be useful for
future therapy development and precision medicine.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2016.01.035.ReferencesBA
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